Kava for Anxiety Relief

Anxiety Relief — scientific infographic poster

Kava (Piper methysticum) has been tested for anxiety in a series of randomized controlled trials (RCTs) with mixed results: the 2013 Sarris trial found a significant reduction in generalized anxiety disorder symptoms versus placebo, the Pittler & Ernst 2003 Cochrane review (11 trials, 645 participants) found a significant reduction in Hamilton anxiety scores in a meta-analysis of six of those trials, and the larger 16-week 2020 Sarris trial found no benefit over placebo. A 2022 guideline from the World Federation of Societies of Biological Psychiatry (WFSBP) and the Canadian Network for Mood and Anxiety Treatments (CANMAT) rated kava as not recommended for generalised anxiety disorder. The mechanism is positive allosteric modulation of gamma-aminobutyric acid-A receptors by the kavalactone class — principally kavain, methysticin, and yangonin — at sites distinct from the benzodiazepine binding pocket, producing anxiolysis without the tolerance, withdrawal, or amnestic effects characteristic of benzodiazepines. This deep-dive walks through the clinical trial evidence, the gamma-aminobutyric acid-A pharmacology, the comparison to benzodiazepines and selective serotonin reuptake inhibitors (SSRIs), and how kava has been used for mild to moderate generalized anxiety.


Table of Contents

  1. The Sarris 2013 Generalized Anxiety Disorder Trial
  2. The Pittler & Ernst 2003 Cochrane Meta-Analysis
  3. The Six Principal Kavalactones
  4. Gamma-Aminobutyric Acid-A Allosteric Modulation Mechanism
  5. Kava versus Benzodiazepines
  6. Kava versus Selective Serotonin Reuptake Inhibitors and Buspirone
  7. Trial History (Volz 1997 to Witte 2005)
  8. A 2018 Review and a 2022 Guideline Weigh the Kava Trials
  9. Dosing and Practical Use for Anxiety
  10. Social Anxiety and Performance Anxiety
  11. Cautions and Drug Interactions
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Sarris 2013 Generalized Anxiety Disorder Trial

One of the main pieces of modern evidence that kava reduces anxiety in clinically diagnosed anxiety disorder is the Sarris et al. 2013 trial, published in the Journal of Clinical Psychopharmacology. The study enrolled 75 adults with DSM-IV diagnosed generalized anxiety disorder and no comorbid mood disorder (Hamilton Anxiety Rating Scale (HAM-A) ≥ 20 at baseline), randomized them double-blind to either an aqueous extract of noble Vanuatu kava cultivar (titrated to 120 mg kavalactones per day for the first three weeks, escalated to 240 mg/day for an additional three weeks if needed) or matched placebo, and measured HAM-A change at 6 weeks.

The results:

The 2013 trial was important because it used a noble Vanuatu cultivar aqueous extract — the traditional preparation type — rather than the acetonic or ethanolic extracts implicated in the 2002 European hepatotoxicity controversy. The clean liver function results at clinical doses are themselves a contribution to the kava safety literature, beyond the primary efficacy finding.

A larger 2020 follow-up trial by Sarris and colleagues tested an aqueous extract of dried kava root (standardised to 120 mg of kavalactones twice a day) for 16 weeks in 171 people with diagnosed generalised anxiety disorder. It found no significant difference from placebo (a relative reduction favouring placebo of 1.37 points; p = 0.25), and 17.4% of the kava group were remitted versus 23.8% of the placebo group. Liver function test abnormalities were significantly more frequent in the kava group, although no participant met criteria for herb-induced liver injury. The authors concluded that this extract was not effective for diagnosed generalised anxiety disorder. Both the 2013 and the 2020 trials used aqueous root extracts.

Back to Table of Contents

The Pittler & Ernst 2003 Cochrane Meta-Analysis

The Pittler and Ernst 2003 Cochrane systematic review included 11 randomized double-blind placebo-controlled trials of kava extract for anxiety, with a total of 645 participants. Six of these studies (345 participants) used the Hamilton Anxiety Rating Scale (HAM-A) total score as a common outcome and were pooled in a meta-analysis, which found a significant reduction in patients receiving kava extract compared with patients receiving placebo (weighted mean difference 5.0 points, 95% confidence interval (CI) 1.1 to 8.8; p = 0.01). Adverse events reported in the reviewed trials were mild, transient and infrequent.

The Cochrane review noted several important caveats:

The 2003 Cochrane review concluded that, compared with placebo, kava extract "appears to be an effective symptomatic treatment option for anxiety" and that the available data suggest it is relatively safe for short-term treatment (1 to 24 weeks), although more information is required; the reviewers called for further rigorous investigation, particularly into the long-term safety profile of kava.

The Pittler Cochrane review and the 2013 Sarris trial are the main positive evidence for kava in anxiety. Against them stand the negative 2002 Connor & Davidson trial and the larger negative 2020 Sarris trial. The 2022 WFSBP and CANMAT guideline rated kava as not recommended for generalised anxiety disorder, while rating ashwagandha and lavender as modestly supported in the treatment of anxiety disorders (see the section on reviews and guidelines below).

Back to Table of Contents

The Six Principal Kavalactones

Kava's bioactivity resides in the kavalactone class — styryl-2-pyranones (also called α-pyrones) concentrated in the root and rhizome of Piper methysticum. Six kavalactones together account for approximately 96% of the kavalactone content of a typical noble-cultivar root preparation:

  1. Kavain (also kawain) — the most extensively studied kavalactone; principal gamma-aminobutyric acid-A allosteric modulator; voltage-gated sodium channel blocker; weak dopamine reuptake inhibitor. Approximately 15–25% of total kavalactones in a typical noble cultivar.
  2. Methysticin — its rank varies by cultivar (in the noble Borogu chemotype 423561 it comes fifth, after kavain, dihydrokavain, yangonin and dihydromethysticin); gamma-aminobutyric acid-A modulator; neuromuscular effects; weak dopamine reuptake inhibitor. Approximately 10–20% of total kavalactones.
  3. Yangonin — pigmented kavalactone with characteristic yellow color; principal monoamine oxidase B (MAO-B) inhibitor among the kavalactone class; relevant to mood effects. Approximately 10–20% of total kavalactones.
  4. Desmethoxyyangonin — structural variant of yangonin with similar MAO-B inhibitory activity; weaker gamma-aminobutyric acid-A activity than kavain. Approximately 5–15% of total kavalactones.
  5. Dihydromethysticin — saturated version of methysticin; longer-acting at gamma-aminobutyric acid-A; implicated in the longer-duration sedative effect of some preparations. Approximately 5–15% of total kavalactones.
  6. Dihydrokavain — saturated kavain analog; significant skeletal muscle relaxant activity; less gamma-aminobutyric acid-A modulation than kavain. Approximately 5–15% of total kavalactones.

The relative proportions of these six kavalactones is highly cultivar-specific and is captured in the "chemotype" notation: a six-digit code (e.g. 462531) indicating the rank order of abundance from highest to lowest. The numbers follow the order in which the six kavalactones come off a high-performance liquid chromatography (HPLC) column: desmethoxyyangonin = 1, dihydrokavain = 2, yangonin = 3, kavain = 4, dihydromethysticin = 5, methysticin = 6. A chemotype 462531 cultivar therefore has kavain (#4) as the most abundant and methysticin (#6) as the second; most noble Borogu samples listed in a 2020 review carry the chemotype 423561 (Bian et al. 2020). Traditional Pacific kava cultivars have specific chemotypes that have been selected over millennia for their balanced anxiolytic-sedative-muscle-relaxant profile. Cultivars with high flavokavain B and pipermethystine content (the tudei cultivars) have historically been used only in restricted ritual contexts because of their less-tolerated psychoactive and toxicity profile.

The chemotype variability also explains why kava research is so methodologically difficult: a clinical trial of a single standardized extract (e.g. a standardised acetone extract titrated to 70% kavalactones) does not necessarily generalize to a different aqueous root preparation of a different cultivar.

Back to Table of Contents

Gamma-Aminobutyric Acid-A Allosteric Modulation Mechanism

The principal anxiolytic mechanism of the kavalactones is positive allosteric modulation of gamma-aminobutyric acid-A receptors — the same receptor class targeted by benzodiazepines, barbiturates, ethanol, neurosteroids, propofol, and zolpidem — but at distinct binding sites with distinct functional consequences.

The gamma-aminobutyric acid-A receptor is a pentameric ligand-gated chloride channel composed of various combinations of subunits (typically two α, two β, and one γ subunit). Gamma-aminobutyric acid (GABA) binding at the α-β interface opens the channel and allows chloride influx, hyperpolarizing the postsynaptic neuron and reducing its excitability. Various allosteric modulators bind at distinct sites on the receptor to enhance (positive modulation) or reduce (negative modulation) gamma-aminobutyric acid's effect:

The kavalactones do not inhibit the binding of the benzodiazepine-site radioligand [3H]flunitrazepam in radioligand binding studies (Boonen et al. 1998, others), indicating their site of action is distinct from the benzodiazepine site. The exact molecular pocket has not been definitively identified, but pharmacological evidence suggests interaction at the β3 subunit or a novel allosteric site. Functional consequences differ from benzodiazepines in three important ways:

  1. No cross-tolerance with benzodiazepines — patients on chronic benzodiazepines do not show reduced response to kava, suggesting non-overlapping mechanism
  2. No flumazenil reversal — the benzodiazepine antagonist flumazenil does not reverse kava-induced anxiolysis, confirming separate sites
  3. Less amnestic effect — kava at clinical doses does not produce the anterograde amnesia characteristic of benzodiazepines, presumably because it does not act at the hippocampally-enriched α5-containing gamma-aminobutyric acid-A subtype that mediates benzodiazepine amnestic effects

The functional implication is that kava provides gamma-aminobutyric acid-A-mediated anxiolysis without the most problematic side effects of benzodiazepines: tolerance, withdrawal syndrome, amnesia, and abuse liability. This pharmacological profile is the reason kava has been proposed for situations where benzodiazepines are poorly tolerated or carry extra risk — including older patients, patients with substance use history, and patients requiring sustained daily use beyond a few weeks.

For broader context on gamma-aminobutyric acid pharmacology and other natural GABAergic modulators, see the Valerian page and the Passionflower page — both work through partially overlapping but distinct gamma-aminobutyric acid mechanisms.

Back to Table of Contents

Kava versus Benzodiazepines

The clinical comparison between kava and benzodiazepines is one of the most important practical questions in botanical anxiolytic medicine. The two classes target overlapping receptor populations but produce meaningfully different clinical profiles.

Where Kava Wins

Where Benzodiazepines Win

In summary, benzodiazepines act faster and more strongly in acute severe anxiety and pre-procedural sedation, while kava's trial evidence concerns mild-to-moderate generalized anxiety, with mixed results (see Trial History below). Other factors that bear on the comparison are history of substance use disorder, age, and concurrent medications.

Back to Table of Contents

Kava versus Selective Serotonin Reuptake Inhibitors and Buspirone

Selective serotonin reuptake inhibitors (sertraline, escitalopram, paroxetine) are first-line pharmacological therapy for generalized anxiety disorder in most modern psychiatric guidelines. Buspirone (a 5-HT1A partial agonist) is a second-line oral agent specifically approved for generalized anxiety disorder (GAD). Kava's place in this hierarchy is not formally established; the 2022 WFSBP and CANMAT guideline rated it as not recommended for GAD. The situations in which kava has been proposed are listed below.

Onset and Time Course

Clinical Niche for Kava

Combination Considerations

Combining kava with selective serotonin reuptake inhibitors is not absolutely contraindicated but warrants caution because the MAO-B inhibitory activity of yangonin and desmethoxyyangonin could theoretically interact with serotonergic medications. In practice, the in vivo MAO-B inhibition appears clinically modest and serotonin syndrome from this combination is not well-documented in case reports, but conservative clinicians avoid the combination. Combining kava with benzodiazepines raises a concern for additive central nervous system (CNS) depression, even though the receptor sites are distinct.

For broader context on natural anxiety remedies and stress management, see our Natural Anxiety Relief page and Stress Management page.

Back to Table of Contents

Trial History (Volz 1997 to Witte 2005)

The clinical trial literature on kava for anxiety spans nearly three decades and includes more than 20 randomized controlled trials. The principal milestones:

The overall pattern across nearly three decades of trials is mixed. The 2009 crossover trial and the 2013 trial of aqueous root extracts were positive, but the larger and longer 2020 trial of an aqueous root extract was negative. Why the large 2009 result and the negative 2020 result differ so much is an open question.

Back to Table of Contents

A 2018 Review and a 2022 Guideline Weigh the Kava Trials

A 2018 systematic review by Smith and Leiras found 11 eligible articles, 7 of them comparing kava with placebo. Kava was more effective than placebo in 3 of those 7 trials. Pooling responder rates from 5 trials (330 people) gave a risk ratio of 1.50 (95% CI 1.12 to 2.01) in kava's favour, and adverse events were no different from placebo (P = 0.574). The authors concluded that kava "appears to be a short-term treatment for anxiety, but not a replacement for prolonged anti-anxiety use", and noted that, although not seen in their review, liver toxicity is "especially possible if taken longer than 8 weeks".

In 2022 an international taskforce of the World Federation of Societies of Biological Psychiatry (WFSBP) and the Canadian Network for Mood and Anxiety Treatments (CANMAT) — 31 academics and clinicians from 15 countries — graded nutrient and plant medicines for psychiatric disorders, looking mainly at meta-analyses and at two or more randomized trials. It rated kava "(-)", not recommended for generalised anxiety disorder. In the same guideline, ashwagandha and lavender were modestly supported in the treatment of anxiety disorders, and chamomile was not currently recommended for generalised anxiety disorder. The guideline also notes that single trials, open-label studies, case studies and traditional use were not assessed, and that an absence of data does not imply lack of efficacy.

Back to Table of Contents

Dosing and Practical Use for Anxiety

Effective anxiolytic dosing for kava is measured in milligrams of total kavalactones per day, not in grams of root or milliliters of preparation. Different products have different kavalactone concentrations, so reading the label for kavalactone content is essential.

Dose Ranges from the Trial Literature

Onset and Duration

Product Selection

Cycling and Duration of Use

Traditional Pacific use is social and ceremonial, not daily medication. For modern anxiolytic use, some practitioners describe cycling the herb — for example, 4 weeks of daily use followed by a 1-week break. A liver monitoring schedule described for daily kava users is liver function testing (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, total bilirubin) before starting and after the first month, with repeats every 3–6 months. A 2018 systematic review notes that liver toxicity is "especially possible if taken longer than 8 weeks".

Back to Table of Contents

Social Anxiety and Performance Anxiety

While most randomized controlled trial evidence for kava concerns generalized anxiety disorder, traditional Pacific use is overwhelmingly in social and ceremonial contexts — a context that maps onto modern Western diagnostic categories of social anxiety disorder and situational performance anxiety. The subjective qualities reported by long-time kava users are precisely those one would want for these conditions: sociable but not euphoric, relaxed but mentally clear, fluent but not impulsive.

Pilot evidence for kava in social anxiety disorder is suggestive but limited. A small open-label study in social phobia patients found measurable improvement on Liebowitz Social Anxiety Scale scores. No large randomized controlled trial has specifically targeted social anxiety disorder as the primary diagnosis.

The use case for kava in performance anxiety (public speaking, stage performance, test-taking, athletic performance, situations where benzodiazepines are problematic because of their cognitive blunting) is supported by mechanistic arguments and by traditional use evidence but not by formal randomized controlled trial (RCT) data. The practical considerations:

For broader context on anxiety conditions, see our Anxiety page.

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Sarris J, Stough C, Bousman CA, et al. (2013). Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology. 33(5):643-8. — PubMed PMID: 23635869
  2. Sarris J, Stough C, Teschke R, et al. (2013). Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects. Phytotherapy Research. 27(11):1723-8. — PubMed PMID: 23348842
  3. Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G (2009). The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl). 205(3):399-407. — PubMed PMID: 19430766
  4. Pittler MH, Ernst E (2003). Kava extract for treating anxiety. Cochrane Database of Systematic Reviews. — PubMed PMID: 12535473
  5. Volz HP, Kieser M (1997). Kava-kava extract [a standardised acetone extract] versus placebo in anxiety disorders — a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry. — PubMed PMID: 9065962
  6. Lehmann E et al. (1996). Efficacy of a special kava extract in patients with states of anxiety. Phytomedicine. — PubMed PMID: 23194958
  7. Connor KM, Davidson JR (2002). A placebo-controlled study of Kava kava in generalized anxiety disorder. International Clinical Psychopharmacology. 17(4):185-8. — PubMed PMID: 12131602
  8. Witte S, Loew D, Gaus W (2005). Meta-analysis of the efficacy of the acetonic kava-kava extract [a standardised extract] in patients with non-psychotic anxiety disorders. Phytotherapy Research. — PubMed PMID: 15934028
  9. Sarris J, Byrne GJ, Bousman CA, et al. (2020). Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Australian and New Zealand Journal of Psychiatry. 54(3):288-297. — PubMed PMID: 31813230
  10. Watkins LL, Connor KM, Davidson JR (2001). Effect of kava extract on vagal cardiac control in generalized anxiety disorder: preliminary findings. Journal of Psychopharmacology. 15(4):283-6. — PubMed PMID: 11769822
  11. Boonen G, Häberlein H (1998). Influence of genuine kavapyrone enantiomers on the GABA-A binding site. Planta Medica. 64(6):504-6. — PubMed PMID: 9776662
  12. Singh YN, Singh NN (2002). Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs. — PubMed PMID: 12383029
  13. Sarris J, Kavanagh DJ (2009). Kava and St. John's wort: current evidence for use in mood and anxiety disorders. Journal of Alternative and Complementary Medicine. — PubMed PMID: 19614563
  14. Smith K, Leiras C (2018). The effectiveness and safety of Kava Kava for treating anxiety symptoms: systematic review and analysis of randomized clinical trials. Complementary Therapies in Clinical Practice. — PubMed PMID: 30396607
  15. Sarris J, Ravindran A, Yatham LN, et al. (2022). Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World Journal of Biological Psychiatry. 23(6):424-455. — PubMed PMID: 35311615
  16. Bian T, Corral P, Wang Y, et al. (2020). Kava as a Clinical Nutrient: Promises and Challenges. Nutrients. 12(10):3044. — PubMed PMID: 33027883

PubMed Topic Searches

  1. PubMed: Kava GAD randomized trials
  2. PubMed: Kavalactone GABA-A modulation
  3. PubMed: Kava vs benzodiazepine
  4. PubMed: Kava acetone-extract anxiety trials
  5. PubMed: Kava social anxiety

Back to Table of Contents

Connections

Back to Table of Contents